<DOC>
	<DOCNO>NCT01353079</DOCNO>
	<brief_summary>The primary objective study demonstrate SLIT administer pre-and co-seasonally effective reduce rhinoconjunctivitis symptom entire short ragweed pollen season .</brief_summary>
	<brief_title>Efficacy Safety Study Of Short Ragweed Pollen Sublingual-Oral Immunotherapy</brief_title>
	<detailed_description />
	<criteria>allergic ragweed allergic ragweed history anaphylaxis subject chronic sinusitis , unstable angina , significant arrhythmia , uncontrolled hypertension , chronic immunological disease Asthmatic subject FEV1 PEF less equal 80 % predicted Subjects receive experimental drug within 30 day prior study admission Subjects receive anitIgE medication last 12 month Subjects receive ragweed immunotherapy last 3 year Subjects currently user inhale , intramuscular , intravenous corticosteroid , tricyclic antidepressant , beta blocker , MAO inhibitor Subjects refuse sign epipen train form Females pregnant breast feeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 2015</verification_date>
</DOC>